- Home
- VSTM
VSTM
Verastem Inc.
as 03-28-2025 4:00pm EST
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.
| Founded: | 2010 | Country: | United States |
| Employees: | N/A | City: | NEEDHAM |
| Market Cap: | 313.1M | IPO Year: | 2012 |
| Target Price: | $13.00 | AVG Volume (30 days): | 949.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.66 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.10 - $13.52 | Next Earning Date: | 03-20-2025 |
| Revenue: | $10,000,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | 98.93% | Revenue Growth (next year): | 231.26% |
Stock Insider Trading Activity of Verastem Inc. (VSTM)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Calkins Daniel | VSTM | Chief Financial Officer | Mar 20 '25 | Sell | $6.97 | 91 | $630.89 | 86,348 | |
| Gagnon Robert E. | VSTM | Director | Mar 17 '25 | Sell | $6.95 | 284 | $1,973.80 | 34,193 | |
| Stuglik Brian M | VSTM | Director | Mar 17 '25 | Sell | $6.95 | 593 | $4,121.35 | 94,587 | |
| Paterson Dan | VSTM | President and CEO | Feb 4 '25 | Sell | $5.70 | 858 | $4,890.60 | 346,723 | |
| Paterson Dan | VSTM | President and CEO | Jan 10 '25 | Sell | $5.24 | 8,568 | $44,896.32 | 346,723 | |
| Calkins Daniel | VSTM | Chief Financial Officer | Jan 6 '25 | Sell | $6.94 | 6 | $41.64 | 86,348 |
Latest Verastem Inc. News
VSTM Breaking Stock News: Dive into VSTM Ticker-Specific Updates for Smart Investing
Zacks
2 days ago
Wall Street Analysts Believe Verastem (VSTM) Could Rally 100.94%: Here's is How to Trade
Business Wire
4 days ago
Verastem Oncology Announces Multiple Presentations Focused on RAS/MAPK Pathway Inhibition at AACR Annual Meeting 2025
MT Newswires
8 days ago
RBC Cuts Price Target on Verastem to $14 From $16, Maintains Outperform Rating
Associated Press Finance
9 days ago
Verastem: Q4 Earnings Snapshot
Business Wire
9 days ago
Verastem Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates
Business Wire
a month ago
Verastem Oncology Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Women’s Cancer
MT Newswires
2 months ago
B. Riley Adjusts Verastem's Price Target to $9 From $7, Maintains Buy Rating
Business Wire
2 months ago
Verastem Oncology to Present at the Guggenheim SMID Cap Biotech Conference
Compare VSTM vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "VSTM Verastem Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.